Covidien chief Almeida to chair AdvaMed's board

March 26, 2014 by Arezu Sarvestani

Covidien chairman, president & CEO José Almeida is the new chairman of the board of directors at medtech lobbying group AdvaMed.

Covidien chief Almeida joins AdvaMed's board

Medtech lobbying group AdvaMed appointed a new board chairman, tapping Covidien (NYSE:COV) chairman, president & CEO José Almeida for the role.

Almeida has been on the board since 2005 and a member of the executive committee since 2010. He'll serve a 2-year term as chairman, succeeding outgoing chairman and Zimmer Holdings (NYSE:ZMH) president & CEO David Dvorak.

Sign up to get our free newsletters delivered right to your inbox.

Almeida's term will be focused on improving medtech review timelines at the FDA, supporting industry-friendly tax policies and repeal of the medical device excise tax, pursuing streamlining in international healthcare regulation and promoting AdvaMed's ethics in Asia and Latin America.

"Advances in medical technology are allowing patients to live better, longer lives," Almeida said in prepared remarks. "Yet the challenges of getting medical devices and diagnostics into the hands of patients and physicians are still formidable, highlighting the imperative for AdvaMed and continued industry partnership."